HPV16/18 Vaccine Trial for Cervical Lesions
Part of Infections clinical trials.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have tested positive for HPV type 16 or 18, but not have a high-grade cervical lesion (CIN2+).
- You should be at least 18 years old and in reasonably good health (able to do daily activities).
- No weakened immune system, autoimmune diseases (like MS or lupus), or use of steroids that suppress immunity.
- No metal implants, pacemaker, or electronic devices in the body.
- No other cancer within the past 5 years, unless it was a fully removed skin cancer.
- No active infections from HIV, hepatitis B or C, and no history of fainting in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
This early-phase study tests a vaccine designed to help your immune system fight HPV16, a type of human papillomavirus linked to abnormal cells in the cervix. You may or may not be living with HIV, and the team will check safety and immune response after giving the vaccine in a specific way.
This early (Phase 1) study tests a new treatment for people with long-lasting mild abnormal Pap test results (ASC-US or LSIL) who also have HPV16 found on testing. It aims to find out whether the treatment can be given safely and may affect the HPV and abnormal cell changes.
This trial tests an experimental vaccine for women who have HPV type 16 but only mild or no precancerous changes (CIN1 or less). The vaccine uses a special device to help your body's immune system fight the virus, which may prevent it from becoming cervical cancer.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
Hear when a new HPV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.